Purpose: We intend to use big data and machine learning techniques to improve the models to better predict and maintain response to infliximab therapy.

Primary Outcome: Identify predictors for primary non-response and secondary loss of response.

Secondary Outcome: Determine significant time varying features for effective treatment time.

Funding Source: Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number 5T32HD069054 (Cincinnati Training Program in Pediatric Clinical & Developmental Pharmacology; Vinks, Program director).

Study Period: 2020-2022

Recruitment Status: This study makes use of existing data in the ICN registry. No patient recruitment is occurring at this time.

Contact: Ye Xiong 

Built by Veracity Media on NationBuilder